Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Sesen Bio to host business news update conference call » 07:55
07/31/20
07/31
07:55
07/31/20
07:55
SESN

Sesen Bio

$1.01 /

-0.01 (-0.98%)

Management holds July…

Management holds July 2020 business news update conference call on July 31 at 8 am. Webcast Link

ShowHide Related Items >><<
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

Hot Stocks
Sesen Bio announces exclusive license agreement with Qilu Pharmaceutical » 07:32
07/31/20
07/31
07:32
07/31/20
07:32
SESN

Sesen Bio

$1.01 /

-0.01 (-0.98%)

Sesen Bio and Qilu…

Sesen Bio and Qilu Pharmaceutical said in a release, "the companies have entered into an exclusive licensing agreement for the manufacture, development and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, or NMIBC, and other types of cancer in China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Sesen granted Qilu Pharmaceutical an exclusive license to develop and commercialize Vicineum in Greater China. Sesen will receive an upfront payment of $12 million and is eligible to receive up to an additional $23 million in technology transfer and regulatory milestone payments. Upon commercialization in Greater China, Sesen is also entitled to receive royalties on net sales in Greater China. Sesen retains full development and commercialization rights for Vicineum for the treatment of NMIBC in the US and the rest of the world excluding Greater China. The terms of the agreement also include the transfer of the Vicineum manufacturing technology to Qilu Pharmaceutical, whose world-class manufacturing expertise represents a future opportunity for production expansion to meet the anticipated significant global demand for Vicineum for the treatment of NMIBC."

ShowHide Related Items >><<
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

Conference/Events
Sesen Bio to host business news update conference call » 04:55
07/31/20
07/31
04:55
07/31/20
04:55
SESN

Sesen Bio

$1.01 /

-0.01 (-0.98%)

Management holds July…

Management holds July 2020 business news update conference call on July 31 at 8 am. Webcast Link

ShowHide Related Items >><<
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

SESN Sesen Bio
$1.01 /

-0.01 (-0.98%)

Thursday
Conference/Events
Sesen Bio to host business news update conference call » 16:09
07/30/20
07/30
16:09
07/30/20
16:09
SESN

Sesen Bio

$1.02 /

-0.005 (-0.49%)

Management holds July…

Management holds July 2020 business news update conference call on July 31 at 8 am. Webcast Link

ShowHide Related Items >><<
SESN Sesen Bio
$1.02 /

-0.005 (-0.49%)

SESN Sesen Bio
$1.02 /

-0.005 (-0.49%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
SESN Sesen Bio
$1.02 /

-0.005 (-0.49%)

SESN Sesen Bio
$1.02 /

-0.005 (-0.49%)

Over a month ago
Earnings
Sesen Bio reports Q1 EPS 31c, consensus (9c) » 07:09
05/11/20
05/11
07:09
05/11/20
07:09
SESN

Sesen Bio

$0.81 /

+0.0926 (+13.00%)

"In the first…

"In the first quarter of 2020, we successfully completed manufacturing of the pre-PPQ batch at Fujifilm," said Dr. Thomas Cannell, president and CEO of Sesen Bio. "We believe the commercial-scale cGMP batches of Vicinium manufactured to date at our CMOs are comparable to Vicinium previously manufactured by Sesen for use in our clinical trials. This reinforces our confidence in the upcoming PPQ campaign and our ability to demonstrate analytical comparability between clinical and commercial drug supply. The company's focus for 2020 remains the flawless execution of the PPQ campaign and the finalization of Module 3 to complete the Vicinium BLA submission."

ShowHide Related Items >><<
SESN Sesen Bio
$0.81 /

+0.0926 (+13.00%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
Hot Stocks
Sesen Bio reports 'positive' interactions with EMA over vicinium » 16:43
05/07/20
05/07
16:43
05/07/20
16:43
SESN

Sesen Bio

$0.71 /

+0.0847 (+13.49%)

Sesen Bio reported that…

Sesen Bio reported that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the regulatory pathway for Vicinium in Europe. The Company's lead program, Vicinium, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicinium to the United States Food and Drug Administration (FDA) under Rolling Review. "We are very pleased to have received positive guidance from the CHMP on the regulatory approval pathway for Vicinium," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. "We strongly believe that Vicinium is a highly differentiated product candidate that is well positioned to address the considerable unmet need in NMIBC. This encouraging progress reinforces our confidence in bringing Vicinium to market in Europe, which represents a tremendous opportunity for the company. We will continue working collaboratively with the EMA to move Vicinium through the approval process as expeditiously as possible."

ShowHide Related Items >><<
SESN Sesen Bio
$0.71 /

+0.0847 (+13.49%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
Over a quarter ago
On The Fly
Fly Intel: Pre-market Movers » 09:22
03/16/20
03/16
09:22
03/16/20
09:22
NNVC

NanoViricides

$6.81 /

-0.695 (-9.26%)

, MRNA

Moderna

$21.30 /

-0.97 (-4.36%)

, NBEV

New Age Beverages

$1.44 /

-0.01 (-0.69%)

, FCEL

FuelCell

$1.11 /

+0.025 (+2.30%)

, SESN

Sesen Bio

$0.63 /

+0.002 (+0.32%)

, MNK

Mallinckrodt

$3.02 /

-0.36 (-10.65%)

, AMC

AMC Entertainment

$3.22 /

+0.325 (+11.23%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
NNVC NanoViricides
$6.81 /

-0.695 (-9.26%)

MRNA Moderna
$21.30 /

-0.97 (-4.36%)

03/05/20
Fly Intel: Top five analyst downgrades
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/05/20 BofA
Moderna downgraded to Neutral from Buy at BofA
03/04/20 Piper Sandler
Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper
NBEV New Age Beverages
$1.44 /

-0.01 (-0.69%)

03/11/20 Compass Point
New Age Beverages price target lowered to $4 from $9 at Compass Point
07/22/19 Northland
Northland downgrades New Age Beverages on 'more realistic' estimates
07/22/19 Northland
New Age Beverages downgraded to Market Perform from Outperform at Northland
06/10/19 Compass Point
New Age Beverages initiated with a Buy at Compass Point
FCEL FuelCell
$1.11 /

+0.025 (+2.30%)

01/23/20 Craig-Hallum
FuelCell downgraded to Sell at Craig-Hallum
01/23/20 Craig-Hallum
FuelCell downgraded to Sell from Hold at Craig-Hallum
12/11/19 Craig-Hallum
FuelCell reinstated with a Hold at Craig-Hallum
06/06/19
Fly Intel: Top five analyst downgrades
SESN Sesen Bio
$0.63 /

+0.002 (+0.32%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
MNK Mallinckrodt
$3.02 /

-0.36 (-10.65%)

02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
09/10/19 Stifel
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
09/09/19 Stifel
Mallinckrodt price target lowered to $8 from $20 at Stifel
AMC AMC Entertainment
$3.22 /

+0.325 (+11.23%)

03/16/20 Benchmark
AMC Entertainment downgraded to Hold from Buy at Benchmark
03/10/20 Barrington
AMC Entertainment price target lowered to $7 from $12 at Barrington
12/18/19
Fly Intel: Top five analyst downgrades
12/18/19 BofA
BofA/Merrill downgrades AMC Entertainment to Underperform with $7 target
Earnings
Sesen Bio reports Q4 EPS (32c), consensus (8c) » 07:03
03/16/20
03/16
07:03
03/16/20
07:03
SESN

Sesen Bio

$0.63 /

+0.002 (+0.32%)

"2019 was a year of…

"2019 was a year of tremendous progress for Sesen Bio in every way, but especially in terms of our regulatory progress," said Dr. Thomas Cannell, president and CEO of Sesen Bio. "After four pivotal meetings with the FDA and the initiation of our BLA submission in 2019, we now turn our focus to finalizing the BLA for Vicinium and transforming into a commercial-ready organization in 2020. We believe Vicinium is a highly differentiated product candidate with a unique mechanism of action and clinical profile. We look forward to continuing our collaborative relationship with the FDA as we work to bring this important product to patients."

ShowHide Related Items >><<
SESN Sesen Bio
$0.63 /

+0.002 (+0.32%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
Hot Stocks
Xoma announces updates regarding partnered assets in development » 07:46
03/10/20
03/10
07:46
03/10/20
07:46
XOMA

Xoma

$21.45 /

-1.34 (-5.88%)

, NVS

Novartis

$81.46 /

-4.15 (-4.85%)

, SESN

Sesen Bio

$0.76 /

-0.0787 (-9.38%)

, TAK

Takeda Pharmaceutical

$17.49 /

-0.52 (-2.89%)

"Last year two of…

"Last year two of our partners, Novartis and Sesen Bio, announced significant clinical developments that have the potential to offer patients with few treatment options the opportunity to access new therapies that have clinically meaningful benefits," CEO Jim Neal said. Novartis (NVS) licensed assets: Novartis presented first-of-its-kind histology data with iscalimab at the American Transplant Congress. The data showed 60 percent of iscalimab-treated transplant patients have normal kidney histology at least one year after transplant, compared with 0 percent with tacrolimus. The company highlighted iscalimab and its development plans at the Novartis R&D Day on December 5, 2019. Novartis now has seven clinical studies with iscalimab underway. Novartis launched its clinical program for gevokizumab with a clinical study in patients with metastatic colorectal cancer, gastroesophageal cancer, and renal cell carcinoma. Sesen Bio (SESN) reported positive top-line Phase 3 data and subsequently initiated its rolling Biologics License Application filing for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. The company has stated it anticipates completing its filing in the second half of 2020. Takeda (TAK) licensed assets: Takeda expanded the TAK-0794 clinical program and now has four studies ongoing. Takeda and Molecular Templates began enrolling patients in their first TAK-1694 clinical program. Aronora initiated a Phase 2 study with AB002 in patients with end-stage renal disease on chronic hemodialysis. AVEO Oncology expanded the clinical program testing ficlatuzumab and now is studying the compound's potential efficacy in a wide variety of oncology indications. Neal concluded, "The clinical advancements continued into 2020. In February, Rezolute, Inc., announced the launch of its Phase 2b clinical trial for RZ358 in patients with congenital hyperinsulinism. Given the insight we gained into this terrible condition during our early development of this compound and the extraordinary families we met, we are truly hopeful Rezolute succeeds in its development efforts for RZ358."

ShowHide Related Items >><<
XOMA Xoma
$21.45 /

-1.34 (-5.88%)

NVS Novartis
$81.46 /

-4.15 (-4.85%)

02/26/20 Bernstein
Regeneron upgraded to Outperform from Market Perform at Bernstein
02/26/20 Canaccord
Regeneron competitive concerns decrease, Canaccord upgrades to Buy
02/26/20 Credit Suisse
Regeneron price target raised to $510 from $420 at Credit Suisse
02/26/20 Baird
Regeneron downgraded to Neutral from Outperform at Baird
SESN Sesen Bio
$0.76 /

-0.0787 (-9.38%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
TAK Takeda Pharmaceutical
$17.49 /

-0.52 (-2.89%)

02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
Conference/Events
Sesen Bio to hold a conference call » 07:25
12/16/19
12/16
07:25
12/16/19
07:25
SESN

Sesen Bio

$1.10 /

+ (+0.00%)

President & CEO…

President & CEO Cannell holds a conference call to provide a regulatory update for Vicinium on December 16 at 8 am. Webcast Link

ShowHide Related Items >><<
SESN Sesen Bio
$1.10 /

+ (+0.00%)

08/09/19 Laidlaw
Sesen Bio downgraded to Hold from Buy at Laidlaw
06/11/19 H.C. Wainwright
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
02/06/19 Jefferies
Sesen Bio assumed with a Buy at Jefferies
01/04/19 H.C. Wainwright
Sesen Bio downgraded to Neutral from Buy at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.